A single center, double-blind, placebo-controlled, randomized, crossover, Phase II study to assess the effect of Aleglitazar on cardiac energetics and function in patients with uncomplicated Type 2 Diabetes Mellitus and no history of Coronary Artery Disease who are drug-naive or treated with stable Metformin monotherapy

Trial Profile

A single center, double-blind, placebo-controlled, randomized, crossover, Phase II study to assess the effect of Aleglitazar on cardiac energetics and function in patients with uncomplicated Type 2 Diabetes Mellitus and no history of Coronary Artery Disease who are drug-naive or treated with stable Metformin monotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Aleglitazar (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Roche
  • Most Recent Events

    • 10 Jul 2013 Status changed from recruiting to discontinued, according to a Roche media release.
    • 12 Jan 2013 Planned number of patients changed from 38 to 30 as reported by UKCRN.
    • 08 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top